SIMEPREVIR PLUS PEGINTERFERON/RIBAVIRIN COST-EFFECTIVENESS ANALYSIS FOR THE TREATMENT OF CHRONIC GENOTYPE 1 HEPATITIS C IN COLOMBIA

被引：1

作者：

Ariza, J. G. ^{[1
]}

Taborda, A. ^{[2
]}

Naciben, V ^{[3
]}

Heibeck, M. ^{[4
]}

Westerhout, K. Y. ^{[5
]}

机构：

[1] Janssen, Bogota, Colombia

[2] Johnson & Johnson, Sao Paulo, SP, Brazil

[3] Janssen Pharmaceut, Sao Paulo, Brazil

[4] Pharmerit Int, Berlin, Germany

[5] Pharmerit Int, Rotterdam, Netherlands

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 07期

关键词：

D O I：

10.1016/j.jval.2015.09.020

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PIN26

引用

页码：A872 / A872

页数：1

共 50 条

[1] Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naive chronic hepatitis C genotype 1 patients in Japan
Kuwabara, Hiroyo
Westerhout, Kirsten
Treur, Maarten
Cerri, Karin
Mahlich, Joerg
Yatsuhashi, Hiroshi
JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (07) : 502 - 511
[2] Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection
Saab, S.
Gordon, S. C.
Park, H.
Sulkowski, M.
Ahmed, A.
Younossi, Z.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (06) : 657 - 675
[3] Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment
Blatt, Carine Raquel
Storb, Bernd
Muehlberger, Nikolai
Farias, Mareni Rocha
Siebert, Uwe
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 50 (02) : 345 - 352
[4] A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C
Buti, M
Medina, M
Casado, MA
Wong, JB
Fosbrook, L
Esteban, R
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (05) : 687 - 694
[5] Cost-effectiveness of peginterferon α-2b plus ribavirin treatment of chronic hepatitis C with F1 fibrosis
Wong, JB
Poynard, T
Manns, MP
McHutchison, JG
Harvey, J
Albrecht, JK
GASTROENTEROLOGY, 2004, 126 (04) : A718 - A718
[6] COST EFFECTIVENESS OF BOCEPREVIR PLUS PEGINTERFERON ALPHA AND RIBAVIRIN VERSUS PEGINTERFERON ALFA PLUS RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN PREVIOUSLY UNTREATED GENOTYPE I PATIENTS
Fonseca, M.
Tannus, G.
Parisi, E.
VALUE IN HEALTH, 2012, 15 (04) : A139 - A139
[7] COST-EFFECTIVENESS OF TELAPREVIR PLUS PEGINTERFERON/RIBAVIRIN (TVR plus PR) VERSUS PEGINTERFERON/RIBAVIRIN (PR) IN TREATMENT-NAIVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS WITH F2 FIBROSIS IN BRAZIL
Morais, A. D.
Pereira, M. L.
VALUE IN HEALTH, 2013, 16 (07) : A354 - A354
[8] COST-EFFECTIVENESS OF BOCEPREVIR USE IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 WHO FAILED PRIOR TREATMENT WITH PEGINTERFERON/RIBAVIRIN
Chhatwal, Jagpreet
Ferrante, Shannon A.
Dasbach, Erik J.
El Khoury, Antoine
Brass, Clifford A.
Burroughs, Margaret
Bacon, Bruce R.
Esteban, Rafael
Elbasha, Elamin
HEPATOLOGY, 2011, 54 : 801A - 802A
[9] Comparison of simeprevir plus peginterferon/ribavirin and telaprevir plus peginterferon/ribavirin for patients with HCV Genotype 1
Nakajima, Tomoaki
Kimura, Mutuumi
Arakawa, Tomohiro
Kuwata, Yasuaki
Ozeki, Itaru
Sato, Takahiro
Ohmura, Takumi
Hige, Shuhei
Karino, Yoshiyasu
Toyota, Joji
HEPATOLOGY, 2013, 58 : 1140A - 1141A
[10] Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Zeuzem, Stefan
Hezode, Christophe
Bronowicki, Jean-Pierre
Loustaud-Ratti, Veronique
Gea, Francisco
Buti, Maria
Olveira, Antonio
Banyai, Tivadar
Al-Assi, M. Tarek
Petersen, Joerg
Thabut, Dominique
Gadano, Adrian
Pruitt, Ronald
Makara, Mihaly
Bourliere, Marc
Pol, Stanislas
Beumont-Mauviel, Maria
Ouwerkerk-Mahadevan, Sivi
Picchio, Gaston
Bifano, Marc
McPhee, Fiona
Boparai, Navdeep
Cheung, Kin
Hughes, Eric A.
Noviello, Stephanie
JOURNAL OF HEPATOLOGY, 2016, 64 (02) : 292 - 300

← 1 2 3 4 5 →